“…We have recently shown that this degradation is enhanced in the presence of cancer cells, which indicates that the VASH1 protein secreted by ECs is inactivated in the tumor microenvironment . Here, we applied a VASH1 ELISA assay, which detects antiangiogenic 44‐ and 36‐kDa protein, but not inactive 29‐kDa protein, and evaluated the potential value of preoperative plasma VASH1 concentration as a prognostic factor in patients with resected lung cancer. Our analysis revealed that the high plasma VASH1 group showed a lower relapse and death rate than did the low VASH1 group throughout the observation period.…”